Mon Oct 27 07:34:31 UTC 2025: ## COVID-19 Vaccines Show Promise as ‘Off-the-Shelf’ Cancer Treatment Booster

Berlin, Germany – mRNA vaccines, rapidly developed and deployed during the COVID-19 pandemic, may hold a surprising key to improving cancer treatment outcomes, according to a new study presented at the European Society for Medical Oncology Congress in Berlin. Researchers from the University of Florida and the University of Texas MD Anderson Cancer Center have found that these vaccines can “wake up” the immune system, making it more effective at fighting tumors, potentially leading to longer survival rates for cancer patients.

The study, published in Nature, analyzed data from over 1,000 cancer patients and revealed that those who received an mRNA COVID-19 vaccine within 100 days of starting immunotherapy lived significantly longer than those who did not. In patients with advanced lung cancer, the median survival rate nearly doubled in vaccinated individuals. Notably, the survival improvements were most pronounced in patients with “cold” tumors, which are typically harder for the immune system to recognize and attack.

“These vaccines produce powerful anti-tumour immune responses that are associated with massive improvements in survival for patients with cancer,” said Dr. Adam Grippin, lead researcher.

The researchers also conducted experiments in mice, injecting mRNA vaccines directly into tumors and observing increased alertness in dendritic cells, which help activate T cells to attack cancer cells. This suggests the vaccine acts as an alarm, alerting the immune system to the presence of the tumor and making it more vulnerable to immunotherapy.

While the findings are preliminary, researchers are optimistic about the potential for mRNA vaccines to revolutionize cancer treatment. Dr. Elias Sayour, another study leader, envisions a future where a universal, “off-the-shelf” mRNA cancer vaccine can mobilize and reset the immune response for all cancer patients.

Dr. Grippin and his team are now launching a Phase 3 clinical trial to confirm these initial results and investigate the possibility of integrating COVID-19 mRNA vaccines into the standard of care for cancer patients. If validated, this research could represent a major breakthrough in the fight against cancer.

Read More